BSE - Delayed Quote • INR NATCO Pharma Limited (NATCOPHARM.BO) Follow Compare 1,235.50 -53.45 (-4.15%) At close: January 10 at 3:59:31 PM GMT+5:30 All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Natco Pharma Ltd (BOM:524816) Q2 FY25 Earnings Call Highlights: Robust Revenue and Profit ... Natco Pharma Ltd (BOM:524816) reports a 35.3% revenue increase and 83% profit growth, while navigating future market uncertainties and regulatory challenges. Update: AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents Update: AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents Performance Overview Trailing total returns as of 1/10/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX Return NATCOPHARM.BO S&P BSE SENSEX YTD -11.58% -1.11% 1-Year +46.15% +8.39% 3-Year +38.42% +29.52%